Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120-Reference-Cited by-同舟云学术

Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120

Published:2007-10-01 Issue:2 Volume:46 Page:222-230
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Cleghorn Farley,Pape Jean W,Schechter Mauro,Bartholomew Courtenay,Sanchez Jorge,Jack Noreen,Metch Barbara J,Hansen Marianne,Allen Mary,Cao Huyen,Montefiori David C,Tomaras Georgia D,Gurunathan Sanjay,Eastman Donna J,do Lago Regina F,Jean Sonic,Lama Javier R,Lawrence Dale N,Wright Peter F

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference34 articles.

1. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals.;Beddows;J Virol,1999

2. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.;Bures;AIDS Res Hum Retroviruses,2000

3. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.;Mascola;J Infect Dis,1996

4. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.;Belshe;AIDS,1998

5. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.;Belshe;J Infect Dis,2001

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials;JAIDS Journal of Acquired Immune Deficiency Syndromes;2020-08-15

2. The Evolution of Poxvirus Vaccines;Viruses;2015-04-07

3. Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants;Clinical and Vaccine Immunology;2014-09-24

4. Motivators to participation in medical trials: The application of social and personal categorization;Psychology, Health & Medicine;2013-12

5. Motivators to Participation in Actual HIV Vaccine Trials;AIDS and Behavior;2013-06-05